Eduardo Martinez, MD
Vascular Surgery · Miami, FLNPI 1396845954
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $845 of the $1,053 with a category attached, or 80.3%. It is spread thinly across 23 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $372 and has fallen 56.2% since, to $163 in 2025. That places this record below the midpoint for vascular surgery clinicians in FL, where the typical reported total is $6,364.
Across 36 payments — averaging $29.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$191
- Cook Medical LLC$133
- Medtronic$115
- Irhythm Technologies, Inc.$99
- Smith+Nephew$56
- Cardiovascular Systems Inc.$52
- plus $407 from 17 others
Across 53 payments — averaging $5405.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$286K
What the payments were for
- Consulting fees$172%
- Food & beverage$84580%
- Education$19118%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $191 |
| Cook Medical LLC | 4 | $133 |
| Medtronic(2 entities) | 2 | $115 |
| Irhythm Technologies, Inc. | 1 | $99 |
| Smith+Nephew | 4 | $56 |
| Cardiovascular Systems Inc. | 3 | $52 |
| Vifor Pharma, Inc. | 2 | $48 |
| Kerecis Limited | 1 | $45 |
| Pfizer | 2 | $35 |
| Abbott | 1 | $33 |
| Bard Peripheral Vascular, Inc. | 2 | $33 |
| Bolton Medical Inc | 1 | $31 |
| Bayer | 1 | $27 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Acera Surgical, Inc. | 1 | $18 |
| Davol Inc. | 1 | $17 |
| Z-medica, LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| KCI USA, Inc. | 1 | $15 |
| Portola Pharmaceuticals, LLC | 1 | $13 |
| Lemaitre Vascular, Inc. | 1 | $13 |
| Merck | 1 | $13 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$101
How this compares
$1,053 in reported general payments places this provider in the 15th percentile of 385 vascular surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 115 | $122,636 |
| Pentoxifylline | 235 | $9,086 |
| ClopidogrelClopidogrel Bisulfate | 557 | $5,242 |
| Atorvastatin Calcium | 204 | $2,098 |
| Rosuvastatin Calcium | 67 | $1,087 |
| Cilostazol | 31 | $808 |
| Pantoprazole Sodium | 74 | $799 |
| Famotidine | 12 | $374 |
| Simvastatin | 15 | $136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $35 | $122,636115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 385 vascular surgery providers in Florida.
Other vascular surgery in Miami
- Juan Fleites VazquezMiami$89K
- Tony ShaoMiami$37K
- Samuel TapperStuart$1.3M
- Mariano ArosemenaBradenton$472K
- Manuel Perez IzquierdoOrlando$302K
- Erin MooreJacksonville$300K
- Rajesh MalikNaples$237K
- Charles BaileyTampa$162K
- Joseph WasselleMelbourne$161K
- Joseph RicottaDelray Beach$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.